Pediatric Nephrology

, Volume 26, Issue 10, pp 1919–1920 | Cite as

Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy

  • Antonia BoutsEmail author
  • Leo Monnens
  • Jean-Claude Davin
  • Geertrude Struijk
  • Lodewijk Spanjaard
Open Access
Letter to the Editors


Complement System Hemolytic Uremic Syndrome Paroxysmal Nocturnal Hemoglobinuria Eculizumab Meningococcal Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Spurred by the reported spectacular results of eculizumab treatment in atypical hemolytic uremic syndrome (aHUS) due to aberrations in the complement system, an increasing number of children will receive this treatment in future. The main adverse effect of this therapy is an increased susceptibility to meningococcal infection due to inhibition of the complement system’s membrane-attack complex. In patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab, the reported occurrence of meningococcal infection is between 0% and 1.5% [1, 2, 3]. These data, concerning adult patients, cannot be extrapolated to children because the age-specific incidence of meningococcal disease is much higher in children.

According to the medication guide of the U.S. Food and Drug Administration, a tetravalent unconjugated polysaccharide vaccine (serogroups A, C, Y, W135) has to be provided at least 2 weeks before the first dose of eculizumab. In our opinion, this approach is not sufficient for prevention in many countries, because none of the available vaccines contains a serogroup B antigen [4]. The serogroup distribution among meningococcal infections in The Netherlands is presented in Fig. 1. Since June 2002, a conjugated vaccine against serogroup C has been included in the national immunization program. In 2009, 84% of isolates belonged to serogroup B, 7% to serogroup C, and the remaining to other serogroups, such as X, Y, and W135 [5]. Thus, the advised vaccination only offers limited protection. The peak incidence of serogroup B meningococcal disease is in children younger than 5 years and between the age of 15 to 19 years. Based on the risk of meningococcal infection in children treated with eculizumab and the high prevalence of serogroup B disease that cannot yet be prevented by vaccination, penicillin prophylaxis should not only be considered [6] but strongly advised to patients. Beside this, vaccination with a conjugated vaccine might give better protection than the unconjugated polysaccharide vaccine [7]. Serogroup B prevalence is highest not only in The Netherlands but in the rest of Europe and other parts of the world [8]. The best strategy depends on the distribution of meningococcal serogroups and the availability of vaccines in different countries [9].
Fig. 1

Distribution of meningococcal serogroups 1959–2009 (adapted from Netherlands Reference Laboratory for Bacterial Meningitis, used with permission)


Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.


  1. 1.
    Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, Gaya A, Coyle L, de Castro C, Maciejewski JP, Bessler M, Kroon HA, Rother RP, Hillmen P (2008) Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 111:1840–1847PubMedCrossRefGoogle Scholar
  2. 2.
    Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, Khursigara G, Fu CL, Omine M, Browne P, Rosse W (2010) Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 85:553–559PubMedCrossRefGoogle Scholar
  3. 3.
    Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R (2008) FDA report: eculizumab (Soliris®) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 13:993–1000PubMedCrossRefGoogle Scholar
  4. 4.
    Gardner P (2006) Prevention of meningococcal disease. N Engl J Med 355:1466–1473PubMedCrossRefGoogle Scholar
  5. 5.
    Netherlands Reference laboratory for bacterial meningitis (AMC/RIVM). Bacterial Meningitis in the Netherlands; annual report 2009. Amsterdam: University of Amsterdam, 2010Google Scholar
  6. 6.
    Waters AM, Licht C (2011) aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol 26(1):41–57PubMedCrossRefGoogle Scholar
  7. 7.
    Memish ZA, Dbaibo G, Montellano M, Verghese VP, Jain H, Dubey AP, Bianco V, Van der Wielen M, Gatchalian S, Miller JM (2011) Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licenced-ACWY polysaccharide vaccine with an acceptable safety profile. Ped Infect Dis J 30(4):e56–e62CrossRefGoogle Scholar
  8. 8.
    Harrison LH, Trotter CL, Ramsay ME (2009) Global epidemiology of meningococcal disease. Vaccine 27S:B51–B63CrossRefGoogle Scholar
  9. 9.
    Hart CA, Thomson APJ (2006) Meningococcal disease and its management in children. BMJ 333:685–6090PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s) 2011

Authors and Affiliations

  • Antonia Bouts
    • 1
    Email author
  • Leo Monnens
    • 2
  • Jean-Claude Davin
    • 1
  • Geertrude Struijk
    • 3
  • Lodewijk Spanjaard
    • 4
  1. 1.Department of Pediatric NephrologyEmma Children’s Hospital, Academic Medical CenterAmsterdamThe Netherlands
  2. 2.Department of PhysiologyUniversity Medical Center NijmegenNijmegenThe Netherlands
  3. 3.Department of Nephrology, Division of Internal MedicineAcademic Medical CenterAmsterdamThe Netherlands
  4. 4.Netherlands Reference Laboratory for Bacterial Meningitis, Department of Medical MicrobiologyAcademic Medical CenterAmsterdamThe Netherlands

Personalised recommendations